Skip to content

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
Contact

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
Contact

PUBLICATIONS

NASH, PUBLICATIONS

Interim Analysis of FASCINATE-2 A Phase 2b Randomized, Placebo Controlled Trial Demonstrated Denifanstat Reduces Circulating Saturated Diacylglycerols and Triacylglycerols, Markers of Lipotoxicity

By Graviton / 11/2023

AASLD The Liver Meeting

Denifanstat, a fatty acid synthase (FASN) inhibitor for the treatment of biopsy-proven NASH: A 26-week interim analysis of the FASCINATE-2 Phase 2b trial

By Lehi Vidigal / 06/2023

EASL International Liver Congress

Phase II Investigation of TVB-2640 (denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma

By Graviton / 04/2023

Clinical Cancer Research

Combination of fatty acid synthase inhibitor with tyrosine kinase inhibitors shows synergistic efficacy in HCC preclinical models, a novel potential approach for clinical development

By Graviton / 02/2023

HCC-TAG

Denifanstat (DEN), a first-in-class fatty acid synthase (FASN) inhibitor, significantly reduces plasma tripalmitin, a marker of de novo lipogenesis, in NASH patients in the FASCINATE-1 and FASCINATE-2 clinical studies

By Graviton / 01/2023

NASH-TAG

Serum metabolomic, lipidomic and proteomic profiling identifies new biomarkers associated with the treatment of denifanstat, a fatty acid synthase inhibitor, in NASH patients

By Graviton / 01/2023

NASH-TAG

Correlation between AI-based digital pathology and non-invasive tests (NITs) – baseline data from the FASCINATE-2 phase 2b clinical study of denifanstat in patients with F2/F3 NASH

By Graviton / 11/2022

AASLD The Liver Meeting

A baseline metabolomic signature predicts liver fat (MRI-PDFF) response for denifanstat, a first-in-class, fatty acid synthase (FASN) inhibitor: analysis in FASCINATE-1 and FASCINATE-2 clinical studies

By Graviton / 11/2022

AASLD The Liver Meeting

Serum proteomic profiling reveals that the fatty acid synthase (FASN) inhibitor denifanstat provides metabolic benefits via increasing fibroblast growth factor 19 (FGF19) and decreasing 3-hydroxy-3-methylglutaryl-coa synthase 1 (HMGCS1) in NASH patients

By Graviton / 11/2022

AASLD The Liver Meeting

FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models

By Graviton / 09/2022

Scientific Reports

Post pagination

← Previous 1 2 3 … 8 Next →

Site map

About
Science
Investors
Programs
Contact

About
Science
Investors
Programs
Contact

Contact us

Business Development
bd@sagimet.com

Investors
ir@sagimet.com

Media
media@sagimet.com

Human Resources
hr@sagimet.com

© 2024 Sagimet Biosciences. All Rights Reserved. Terms of Use Agreement | Privacy Policy | Clinical Trial Privacy Notice

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
Contact

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
Contact

Scroll to Top